PD-L1
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
PD-L1
Jul 14, 2024, 06:51 |
Blog
Angelica Petrillo: The value of PD-L1 in Gastric Cancer
Angelica Petrillo, Medical Doctor at the Medical Oncology Unit at Ospedale del Mare in Naples,…
Jul 12, 2024, 23:29 |
Insight
Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC
Biagio Ricciuti shared on X: "Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC…
Jun 1, 2024, 12:35 |
Insight
Duaa Kanan: Check out our abstract on the role of CPS for PD-L1 expression in patients with NSCLC
Duaa Kanan, Internal Medicine Resident Physician at the University of Illinois College of Medicine Peoria,…
May 23, 2024, 07:44 |
Blog
Medigene's Global Research and Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
Medigene AG an immuno-oncology platform company focusing on the discovery and development of differentiated T cell…
May 21, 2024, 15:41 |
Insight
Yakup Ergün: A valuable retrospective study on PD-L1 alteration after NAC in TNBC
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on…
May 18, 2024, 11:30 |
Insight
Tom Powles: Annual meeting of the CARE 1 metastatic 1st line RCC study
Tom Powles, Director of Barts Cancer Center, shared a post on X: “Annual meeting of…
May 12, 2024, 16:18 |
Insight
Patrick Hwu: Insights into CAR design and optimal coupling to inhibit the PD-L1/PD-1 axis
Patrick Hwu shared on X/Twitter: "Science Saturday T-cells gene-modified with chimeric antigen receptors (CAR) can be…
May 10, 2024, 14:58 |
Blog
Lauren Brown: Another insightful article out of the AURORA collaboration
Lauren Brown, PhD Candidate at Westmead Institute for Medical Research, University of Sydney & Medical…
May 6, 2024, 19:10 |
Blog
Erman Akkus: ASCO Ed book on mNSCLC without oncogenic alterations
Erman Akkus, medical oncologist at Ankara Medical University, shared on Twitter/X: "Metastatic NSCLC without oncogenic…
May 2, 2024, 12:56 |
Blog
Susanna F. Greer: An unexpected GOOD sign - tumor associated macrophages and breast cancer
Susanna F. Greer, Chief Scientific Officer at the V Foundation, published the following newsletter on…
Apr 26, 2024, 10:00 |
Insight
Biagio Ricciuti: Our work on long-term outcomes to PD-1 monotherapy by increasing PD-L1 levels in NSCLC is out in JTO and JTO CRR
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''Our work on long-term…
Apr 22, 2024, 18:48 |
Insight
Piotr Wysocki: Single-agent immunotherapy is a wise choice as first-line treatment in elderly, advanced NSCLC patients, irrespectively of PD-L1 expression
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 18, 2024, 10:39 |
Insight
Arya Roy: Such an interesting finding! PD-L1 positivity varies by metastatic location in mTNBC!
Arya Roy, Hematology-Oncology Fellow at the Roswell Park Comprehensive Cancer Center, shared a post by…
Dec 23, 2023, 03:55 |
Blog
Shilpa Gupta: Our work on plat-ineligibility in Metastatic Urothelial Carcinoma and survival outcomes out in the Journal of the JNCI
Shilpa Gupta, Director of Genitourinary Oncology at Cleveland Clinic, shared a post on X/Twitter: "Our…
Sep 24, 2023, 18:03 |
Blog
Pashtoon Murtaza Kasi: The imagery at RareCyte Incorporated will blow your mind.
Quoting Pashtoon Murtaza Kasi, Oncologist and Researcher at Weill Cornel Medicine and New York- Presbyterian…
All:
15
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube